Called IQcast, the feature tells users whether they have a low, medium or high chance of dropping below the target blood glucose range within the next one to four hours. These individual-specific predictions are generated by analyzing data collected through Sugar.IQ app and the Guardian Connect device. The Sugar.IQ app is currently available in the App Store for free download. The FDA-cleared app uses IBM Watson Health's AI and analytics tools to help users see how their glucose levels change during the day, and includes a smart food logging system, motivational insights, a glycemic assistant, a data tracker and a glycemic insights feature. Hypoglycemia -- defined by the American Diabetes Association as a blood glucose level lower than 70 mg/dL -- can lead to symptoms ranging from lightheadedness and lethargy to vision impairment and seizures.
New mobile app from Medtronic, Sugar.IQ, applies AI technology from IBM Watson Health to help people with diabetes make more informed decisions. Self-driving cars may not be here yet, but artificial intelligence is being used today to help patients with diabetes to manage their glucose. IBM announced its advancement in using artificial intelligence (AI), machine learning, and analytic technologies to address the data-driven obstacles of diabetes, as presented at the American Diabetes Association's (ADA) 78th Scientific Sessions. Through IBM Watson Health's ongoing partnership with Medtronic, the companies announced the commercial availability of Sugar.IQ with Watson, an app that aims to give people insights to help manage their diabetes. They also announced findings from three data presentations at ADA, including real-world data underscoring the value of machine learning and analytic tools in diabetes.
Medtronic and IBM's Watson Health unit outlined a tool to predict whether a diabetic person will have low glucose even within an upcoming 1- to 4-hour window. The feature, called IQcast, is part of the Sugar.IQ personal diabetes app, which is available on Apple's iOS platform. The tool uses IBM's artificial intelligence and Medtronics diabetes devices. For IBM, the Medtronic collaboration is part of a broader wellness technology push leading up to CES 2019. IBM CEO Ginni Rometty is giving a keynote speech revolving in part around AI. Also last month, IBM highlighted how it was combining AI and fingernail sensors to better monitor health and disease.
From diagnostic fingernail sensors to the use of its Watson platform to help invent new drugs, IBM has impressively positioned itself at the forefront of medical tech. Today, January 3, it announced the latest project in this field: a new mobile app feature that's designed to work as an early warning sign for diabetics about the perils of "going low" on their blood sugar levels. To the uninitiated, keeping these blood sugar levels in check sounds easy: Simply avoid eating food with too much sugar and you're good to go. However, the reality is that things are more complicated than that. A person living with type 1 diabetes has to make upwards of 180 decisions every single day, all of which can affect their well being.
IBM's Watson technology will be used in a new diabetes app aimed at identifying patterns in lifestyle and health that could drive better treatment and disease management. Medtronic's Sugar.IQ with Watson cognitive app, which is being piloted, provides real-time continuous glucose monitoring and insulin insight gathered from pumps and glucose sensors, it announced last week. The software tool uncovers behaviors associated with glucose patterns and provides users with real-time personalized information to spur specific actions and to boost understanding of how habits affect glucose levels. In June, IBM and the American Diabetes Association formed a partnership with a goal of developing a personalized mHealth app that gets smarter over time and works with Watson Care Manager. The entities also announced the launch of a diabetes-focused app development challenge for tools that tap the association's deep data and IBM Watson's cognitive insights.